<code id='FFDC8CAD41'></code><style id='FFDC8CAD41'></style>
    • <acronym id='FFDC8CAD41'></acronym>
      <center id='FFDC8CAD41'><center id='FFDC8CAD41'><tfoot id='FFDC8CAD41'></tfoot></center><abbr id='FFDC8CAD41'><dir id='FFDC8CAD41'><tfoot id='FFDC8CAD41'></tfoot><noframes id='FFDC8CAD41'>

    • <optgroup id='FFDC8CAD41'><strike id='FFDC8CAD41'><sup id='FFDC8CAD41'></sup></strike><code id='FFDC8CAD41'></code></optgroup>
        1. <b id='FFDC8CAD41'><label id='FFDC8CAD41'><select id='FFDC8CAD41'><dt id='FFDC8CAD41'><span id='FFDC8CAD41'></span></dt></select></label></b><u id='FFDC8CAD41'></u>
          <i id='FFDC8CAD41'><strike id='FFDC8CAD41'><tt id='FFDC8CAD41'><pre id='FFDC8CAD41'></pre></tt></strike></i>

          hotspot

          hotspot

          author:Wikipedia    Page View:345
          Grail

          Grail spent more than $1 million last quarter lobbying Congress, underscoring the urgency of the company’s bid to secure Medicare coverage for its pricey blood-based cancer screening test that has been on the market for over a year but is not widely used.

          A recently posted lobbying report indicates that, during the fourth quarter of last year, the biotech spent $1.07 million on “issues related to oncology and multi-cancer early detection,” including House and Senate bills that would allow Medicare to cover multi-cancer screening tests. That figure has been rising; during the fourth quarter of 2021, the company spent $470,000 on lobbying. That’s far more than cancer and genetic testing biotechs such as Guardant Health, Myriad Genetics, and Tempus, which spent anywhere from $90,000 to nearly $300,000 on lobbying last quarter.

          advertisement

          The growing investment in lobbying elected officials comes at a time when Grail is looking to make its test, Galleri, available to a broader swath of the population. The test, launched in 2021, can detect early signs of more than 50 cancers among people who don’t have symptoms. That’s because cancer cells release bits of DNA into the bloodstream, and Galleri spots telltale modifications to this DNA.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline
          Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

          Bayer'sU.S.president,SebastianGuth,emphasizedataninterviewattheSTATofficesinBostonthatthepharmacompa

          read more
          Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen
          Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

          1:19Ademonstratorrunsonthethirdnightofprotestssparkedbythefatalpoliceshootingofa17-year-olddriverint

          read more

          Medicare coverage of Wegovy, once blocked, now looks possible

          SteffenTrumpf/picturealliance/GettyImagesWASHINGTON— NovoNordisk’snewlywonpermissiontomarkettheheart